Revised Annual Report for the Financial Year 2024-25.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astonea Labs has resubmitted its revised Annual Report for FY 2024-25 after originally filing it on December 3, 2025. The revision was made because certain pages were inadvertently omitted in the first version, and a Corrigendum dated December 16, 2025 was issued to withdraw one AGM agenda item. The company confirmed there is no change in financial results, audit opinion, or any material outcome — the revisions are administrative only. The AGM was conducted on December 27, 2025. The report highlights the company's focus on pharmaceuticals and cosmetics/personal care, with growth plans around R&D expansion, global market entry, digital transformation, and ESG practices, in preparation for an upcoming stock listing.
This is a procedural/compliance filing with no change to financials or audit opinion, so it is neutral for shareholders. The reaffirmation of an upcoming listing may attract investor interest, but no concrete financial targets or quantified guidance were disclosed.